GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

Summary

This study is a prospective single-arm open-label clinical trial, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune diseases. A total of 10 subjects will be enrolled in this study.

Timeline

Start

2025-08-22

Primary completion

2028-08-21

Completion

2028-08-21

Drugs

Indications